Recommandations de la Société francaise de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite

[1]  J. Primdahl,et al.  Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis , 2016, Annals of the Rheumatic Diseases.

[2]  M. Dougados,et al.  Classification criteria versus physician's opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. , 2017, Joint, bone, spine : revue du rhumatisme.

[3]  M. Dougados,et al.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force , 2017, Annals of the rheumatic diseases.

[4]  F. Mckenna,et al.  The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia , 2018, Rheumatology.

[5]  G. Macfarlane,et al.  Co‐Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia , 2017, Arthritis & rheumatology.

[6]  G. Macfarlane,et al.  Disease Severity in Never Smokers, Ex‐Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis , 2017, Arthritis care & research.

[7]  M. Dougados,et al.  Remission is related to CRP and smoking in early axial spondyloarthritis. The DESIR cohort. , 2017, Joint, bone, spine : revue du rhumatisme.

[8]  A. Deodhar,et al.  Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. , 2017, Seminars in arthritis and rheumatism.

[9]  M. Guerra,et al.  The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review. , 2017, Seminars in arthritis and rheumatism.

[10]  M. Dougados,et al.  Evaluation of whether extremely high enthesitis or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores suggest fibromyalgia and confound the anti-TNF response in early non-radiographic axial spondyloarthritis. , 2017, Clinical and experimental rheumatology.

[11]  D. Elewaut,et al.  Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study , 2017, Annals of the rheumatic diseases.

[12]  R. Landewé,et al.  Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis , 2017, RMD Open.

[13]  M. Dougados,et al.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.

[14]  R. Landewé,et al.  Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis , 2017, RMD Open.

[15]  P. Emery,et al.  Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study , 2016, Annals of the rheumatic diseases.

[16]  J. Primdahl,et al.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update , 2016, Annals of the rheumatic diseases.

[17]  A. Deodhar,et al.  Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study , 2016, Annals of the rheumatic diseases.

[18]  M. Dougados,et al.  Diagnostic delay in axial spondyloarthritis: A cross-sectional study of 432 patients. , 2017, Joint, bone, spine : revue du rhumatisme.

[19]  A. Deodhar,et al.  Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study , 2016, Arthritis Research & Therapy.

[20]  J. Tebib,et al.  Fibromyalgia in Spondyloarthritis: Effect on Disease Activity Assessment in Clinical Practice , 2016, The Journal of Rheumatology.

[21]  C. Prati,et al.  Kinases inhibitors and small molecules: A new treatment tool for axial spondyloarthropathy? , 2016, Joint, bone, spine : revue du rhumatisme.

[22]  P. Mease,et al.  Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study , 2016, The Journal of Rheumatology.

[23]  A. Sharabi,et al.  The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study , 2016, The Journal of Rheumatology.

[24]  M. Cutolo,et al.  A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial , 2016, The Journal of Rheumatology.

[25]  D. M. van der Heijde,et al.  Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis , 2016, Arthritis & rheumatology.

[26]  C. Prati,et al.  Spondyloarthritis and fibromyalgia: interfering association or differential diagnosis? , 2016, Clinical Rheumatology.

[27]  A. Chhabra,et al.  Ankylosing Spondylitis and Axial Spondyloarthritis. , 2016, The New England journal of medicine.

[28]  M. Dougados,et al.  Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. , 2016, Joint, bone, spine : revue du rhumatisme.

[29]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis , 2016, Arthritis & rheumatology.

[30]  P. Goupille,et al.  TNFα antagonist therapy in axial spondyloarthritis: Can we do better? , 2016, Joint, bone, spine : revue du rhumatisme.

[31]  J. Braun,et al.  High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort , 2016, Annals of the rheumatic diseases.

[32]  C. Prati,et al.  Remission in axial spondyloarthritis: The ultimate treatment goal? , 2016, Joint, bone, spine : revue du rhumatisme.

[33]  T. Winzenberg,et al.  Exercise for ankylosing spondylitis: An evidence-based consensus statement. , 2016, Seminars in arthritis and rheumatism.

[34]  C. Edwards,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.

[35]  D. Wendling.  An overview of investigational new drugs for treating ankylosing spondylitis , 2016, Expert opinion on investigational drugs.

[36]  L. Jacobsson,et al.  Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden , 2016, The Journal of Rheumatology.

[37]  M Cutolo,et al.  European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update , 2015, Annals of the rheumatic diseases.

[38]  M. Dougados,et al.  Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study , 2015, Annals of the rheumatic diseases.

[39]  J. Smolen,et al.  Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score , 2015, Annals of the rheumatic diseases.

[40]  M. Ward,et al.  Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials , 2015, Annals of the rheumatic diseases.

[41]  H. Mann,et al.  A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study , 2014, Annals of the Rheumatic Diseases.

[42]  L. Coates,et al.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial , 2014, The Lancet.

[43]  M. Dougados,et al.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. , 2015, The New England journal of medicine.

[44]  M. Dougados,et al.  Spondyloarthritis: A concept or a disease? , 2015, Joint, bone, spine : revue du rhumatisme.

[45]  D. Wendling,et al.  Spondyloarthritis: Criteria, limitations, and perspectives throughout history. , 2015, Joint, bone, spine : revue du rhumatisme.

[46]  J. Kremer,et al.  Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry , 2015, RMD Open.

[47]  A. Gottlieb,et al.  Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial , 2015, Arthritis care & research.

[48]  D. M. van der Heijde,et al.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. , 2015, The New England journal of medicine.

[49]  M. Dougados,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis , 2015, Arthritis & rheumatology.

[50]  A. Gottlieb,et al.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[51]  O. FitzGerald,et al.  Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. , 2015, Annals of the rheumatic diseases.

[52]  P. Rahman,et al.  Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis , 2015, Arthritis & rheumatology.

[53]  Hui Liang,et al.  Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis , 2015, Clinical Rheumatology.

[54]  D. M. van der Heijde,et al.  Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab , 2014, Rheumatology.

[55]  A. Loft,et al.  Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry , 2014, Annals of the rheumatic diseases.

[56]  L. Jacobsson,et al.  Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: data from a Swedish population-based cohort , 2015, Clinical Rheumatology.

[57]  M. Dougados,et al.  Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial , 2014, Arthritis & rheumatology.

[58]  M. Dougados,et al.  Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort , 2014, Annals of the rheumatic diseases.

[59]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[60]  A. Gottlieb,et al.  Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials , 2014, Annals of the rheumatic diseases.

[61]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[62]  E. Theander,et al.  Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA) , 2013, Annals of the rheumatic diseases.

[63]  M. Dougados,et al.  Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. , 2014, Joint, bone, spine : revue du rhumatisme.

[64]  Sergio Gutierrez-Ureña,et al.  A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study , 2013, Annals of the rheumatic diseases.

[65]  G. Shaddick,et al.  Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis , 2013, Annals of the rheumatic diseases.

[66]  M. Brown,et al.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) , 2012, Annals of the rheumatic diseases.

[67]  J. Braun,et al.  First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. , 2012, Rheumatology.

[68]  J. Braun,et al.  Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. , 2012, Rheumatology.

[69]  M. Dougados,et al.  European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies , 2011, Annals of the rheumatic diseases.

[70]  D. M. van der Heijde,et al.  A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis , 2011, Annals of the rheumatic diseases.

[71]  M. Dougados,et al.  2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis , 2011, Annals of the rheumatic diseases.

[72]  M. Dougados,et al.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[73]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[74]  F Guillemin,et al.  EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees , 2004, Annals of the rheumatic diseases.